ES2176334T3 - El uso de gabapentin en el tratamiento de la ansiedad y el panico. - Google Patents

El uso de gabapentin en el tratamiento de la ansiedad y el panico.

Info

Publication number
ES2176334T3
ES2176334T3 ES95926249T ES95926249T ES2176334T3 ES 2176334 T3 ES2176334 T3 ES 2176334T3 ES 95926249 T ES95926249 T ES 95926249T ES 95926249 T ES95926249 T ES 95926249T ES 2176334 T3 ES2176334 T3 ES 2176334T3
Authority
ES
Spain
Prior art keywords
treatment
gabapentin
anxiety
panic
terminal sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926249T
Other languages
English (en)
Inventor
Geoffrey Neil Woodruff
Nicolas S Gee
Lakhbir Singh
Jason P Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/445,398 external-priority patent/US5792796A/en
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2176334T3 publication Critical patent/ES2176334T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS USOS DE AMINOACIDOS CICLICOS CONOCIDOS. TALES COMPUESTOS TALES COMO LA GABAPENTINA SON UTILES EN EL TRATAMIENTO DE LA ANSIEDAD Y EN EL TRATAMIENTO Y/O PREVENCION DE ATAQUES DE PANICO. SE HA DETERMINADO QUE LA SECUENCIA N LAZA A LA GABAPENTINA ES IDENTICA A LA SECUENCIA N DE LA SUBUNIDAD {AL}{SUB,2}{DE} MADURA DEL CANAL CA{SUP,2+} TIPO L DEL MUSCULO ESQUELETICO DE LOS CONEJOS.
ES95926249T 1994-07-27 1995-07-11 El uso de gabapentin en el tratamiento de la ansiedad y el panico. Expired - Lifetime ES2176334T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28128594A 1994-07-27 1994-07-27
US08/445,398 US5792796A (en) 1994-07-27 1995-06-06 Methods for treating anxiety and panic

Publications (1)

Publication Number Publication Date
ES2176334T3 true ES2176334T3 (es) 2002-12-01

Family

ID=26960801

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926249T Expired - Lifetime ES2176334T3 (es) 1994-07-27 1995-07-11 El uso de gabapentin en el tratamiento de la ansiedad y el panico.

Country Status (18)

Country Link
EP (1) EP0804182B1 (es)
JP (1) JPH10503490A (es)
AT (1) ATE218334T1 (es)
AU (1) AU703428B2 (es)
CA (1) CA2193384C (es)
CZ (1) CZ291757B6 (es)
DE (1) DE69526972T2 (es)
DK (1) DK0804182T3 (es)
ES (1) ES2176334T3 (es)
HU (4) HU0102043D0 (es)
MX (1) MX9606674A (es)
NZ (1) NZ290050A (es)
PL (1) PL187064B1 (es)
PT (1) PT804182E (es)
RO (1) RO120041B1 (es)
RU (1) RU2168982C2 (es)
SK (1) SK283711B6 (es)
WO (1) WO1996003122A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712158A (en) * 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
JP3693258B2 (ja) 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
US6635673B1 (en) 1997-10-27 2003-10-21 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
EP1082306A1 (en) * 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
CA2384911C (en) * 1999-09-16 2008-07-22 Warner-Lambert Company Method for the screening of .alpha.2. delta.-1 subunit binding ligands
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
SG48288A1 (en) * 1992-05-20 1998-04-17 Univ Northwestern Gaba and l-glutamic acid analogs for antiseizure treatment

Also Published As

Publication number Publication date
DE69526972T2 (de) 2002-11-21
CA2193384A1 (en) 1996-02-08
AU703428B2 (en) 1999-03-25
HU223841B1 (hu) 2005-02-28
SK9097A3 (en) 1998-05-06
ATE218334T1 (de) 2002-06-15
SK283711B6 (sk) 2003-12-02
PL187064B1 (pl) 2004-05-31
HU0102040D0 (en) 2001-07-30
NZ290050A (en) 1999-08-30
PL318268A1 (en) 1997-05-26
HUT76835A (en) 1997-11-28
CZ291757B6 (cs) 2003-05-14
MX9606674A (es) 1997-03-29
HU0102041D0 (en) 2001-07-30
RO120041B1 (ro) 2005-08-30
PT804182E (pt) 2002-10-31
DE69526972D1 (de) 2002-07-11
WO1996003122A3 (en) 1996-07-18
EP0804182B1 (en) 2002-06-05
DK0804182T3 (da) 2002-09-09
WO1996003122A2 (en) 1996-02-08
JPH10503490A (ja) 1998-03-31
RU2168982C2 (ru) 2001-06-20
CZ16297A3 (en) 1997-07-16
CA2193384C (en) 2002-03-19
EP0804182A2 (en) 1997-11-05
AU3006995A (en) 1996-02-22
HU0102043D0 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
EA200000933A1 (ru) Пептидные композиции и препараты и их применение
CA2178728A1 (en) Skin tanning compositions
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
ES548052A0 (es) Procedimiento para preparar peptidos
NO955067D0 (no) FVII/TF peptider
KR910007960A (ko) 항응고성 펩티드
ATE42308T1 (de) Pharmakologisch aktive peptide.
HUP9602024A2 (hu) Aminosavtartalmú, külsőlegesen használható, gyógyhatású készítmény
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
BG101846A (en) HUMAN DNase I VARIANTS
ATE92078T1 (de) Pharmakologisch aktive peptide.
Leaver Studies on certain peptide fractions isolated from human dentine
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
BG101847A (en) Human dnase i variants